滋阴清热方治疗对甲状腺功能亢进症阴虚火旺证患者疗效、血浆内皮素-1、炎症因子和免疫功能的影响

目的:研究滋阴清热方治疗对甲状腺功能亢进症阴虚火旺证患者疗效、血浆内皮素-1、炎症因子和免疫功能的影响。方法:将广州市花都区妇幼保健院收治的100例甲状腺功能亢进症阴虚火旺证患者分成观察组和对照组。对照组:给患者使用常规药物治疗;观察组:在对照组的基础上,给予滋阴清热方治疗。干预后,比较两组患者的临床疗效、血浆内皮素-1(Endothelin,ET)、炎症因子[白介素-2(Interleukin-2,IL-2)、白介素-8(Interleukin-8,IL-8)]及肿瘤坏死因子(Tumour Necrosis Factor-α,TNF-α)和免疫功能(CD3^+、CD4^+、CD8^+及CD4^+/CD8^+)。结果:干预前,两组患者IL-2、IL-8及TNF-α无变化,差异无统计学意义(P>0.05);干预后,观察组患者的IL-2比对照组高,且对照组的IL-8及TNF-α比观察组的高,P<0.05,差异有统计学意义;干预前,两组患者的CD3^+、CD4^+、CD8^+及CD4^+/CD8^+与ET无变化;干预后,观察组的CD3^+、CD4^+、CD8+及CD4^+/CD8^+比对照组高,P <0.05,差异有统计学意义,且观察组的ET低于对照组且观察组总有效率明显高于对照组。结论:滋阴清热方治疗降低了血浆内皮素-1,减少炎症的出现,提高免疫功能。     

131Ⅰ治疗非Graves'甲状腺功能亢进及非毒性甲状腺肿后诱发Graves'病

~(131)I治疗非Graves’甲亢及非毒性甲状腺肿后数月,少部分患者体内出现促甲状腺激素受体抗体并诱发Graves’病(GD),发病率在0．05%～5%之间。其发病机制假说有通过自身免疫反应介导等。通过监测体内甲状腺自身抗体水平变化、甲状腺显像,可以预测~(131)I治疗后GD的发生。其治疗方法有抗甲状腺药物治疗、再次放射性~(131)I治疗、手术治疗。     

非右房肥大的P波高电压(附39例临床分析)

本文报告39例临床上除外右房肥大的P波高电压,此种P波高电压主要见于冠心病及急性颅脑疾患,二者之和占76.9%。其形态64%与肺性P波相同。产生的机制可能与结间束传导阻滞、中枢调节机能受累、交感神经兴奋性增高等有关。     

甲状腺功能亢进症患者血清锌、铁、铜、钙的测定及意义

目的探讨甲状腺功能亢进症病人血清中Zn、Fe、Cu、Ca浓度的变化及其意义。方法检测30例患者血清中Zn、Fe、Cu、Ca4种元素,同时随机检测与甲亢患者年龄构成比相匹配的30例正常体检者作正常对照。结果甲状腺功能亢进症患者血清中Zn、Fe、Cu元素水平明显高于对照组(P<0.01),两组间Ca浓度比较无统计学意义。结论甲亢患者体内可出现多种元素的代谢异常,此变化既能反应病人机体代谢紊乱程度,同时也可以作为病情监测的参考指标。血清Fe、Zn、Cu的测定对反映甲亢的病情控制及预后判断有一定的临床价值。     

Cav1.1基因26内含子67位点A/G多态性与甲状腺功能亢进性周期性瘫痪的相关性研究

目的探讨钙通道α1亚基（Cav1．1）基因26内含子-67A／G多态性与男性甲状腺功能亢进（简称甲亢）性周期性瘫痪（TPP）的相关性。方法采用多聚酶链反应-单链构象多态性（PCR-SSCP）方法检测46例男性TPP患者（TPP组）、68例男性甲亢患者（GD组）和72名男性健康对照者（CON组）Cav1．1基因26内含子-67A／G多态性。分析比较此多态位点基因型和等位基因在不同人群中分布的差异。结果（1）TPP组、GD组及CON组AG＋GG基因型频率分别为47．83％、14．71％、29．17％，G等位基因频率分别为44．57％、13．24％、27．78％。（2）TPP组AG＋GG基因型频率明显高于GD组和CON组（OR=5．32，P〈0．01；OR=2．23，P=0．04），TPP组G等位基因频率明显高于GD组和CON组（OR=5．27，P〈0．01；OR=2．09，P=0．008）。结论Cav1．1基因26内含子-67位点A／G多态性与男性TPP有相关性。     

内镜治疗甲状腺功能亢进7例报告

目的总结内镜治疗甲状腺功能亢进（甲亢）的经验。方法7例原发性或继发性甲亢，内镜经胸人路行甲状腺全切或次全切除术。结果7例手术均成功，无中转开放手术。手术时间130～260min，平均168min；术中出血量10～200ml，平均70ml。无喉返、喉上神经损伤，无术后出血等并发症。术后恢复良好，近期随访美容效果满意。随访1～12个月，平均5．1月，无复发，2例出现甲状腺功能低下，1例在术后2个月时恢复。结论内镜治疗甲亢技术安全、可行。除常规手术前甲亢准备外，必须行CT检查确认腺体大小，确定残留腺体的大小和位置。     

Outpatient management of patients with large multinodular goitres treated with fractionated radioiodine

The efficacy of fractionated out-patient radioiodine therapy in 38 patients with compressive symptoms due to long-standing large multinodular goitres was assessed. The diagnosis was established by clinical assessment in addition to technetium-99m pertechnetate thyroid scan or computed tomography scan of the thyroid and mediastinum. Oral iodine-131 therapy was administered as a 2.22 GBq (60 mCi) cumulative dose over 4 months (555 MBq per month). All patients were monitored with serum thyroid-stimulating hormone and free thyroxine (± free tri-iodothyronine) assays before the treatment and after each dose fraction. Clinical and biochemical follow-up was performed on all patients and ranged from 6 to 45 months after therapy. The patients consisted of 35 female and three male patients with a median age of 59 years (range 37–87 years). Prior to treatment 20 patients were biochemically hyperthyroid and 18 were euthyroid. Overall, 71% of patients reported a subjective improvement in compressive symptoms and 29% reported no change. Clinically assessed reduction in goitre size occurred in 92% of patients while there was no change in 8%. At 3 months of follow-up, 31% of patients had become hypothyroid and at 18 months 66% were hypothyroid. Seven hyperthyroid patients (35%) became euthyroid and 13 hyperthyroid patients (65%) became hypothyroid. Three patients who became hypothyroid experienced neck soreness (transient in one patient, persistent in two patients). There were no differences in outcome between patients who were hyperthyroid and those who were euthyroid prior to treatment. Fractionated out-patient radioiodine therapy showed excellent short- and medium-term safety, was very well tolerated and offered a satisfactory alternative treatment to surgery. Received 23 May and in revised form 11 August 1997     

甲状腺功能亢进性心脏病的围术期处理

目的探讨甲状腺功能亢进（甲亢）性心脏病的围术期处理的方法与效果。方法对98例甲亢性心脏病围手术期的处理措施和效果结合文献进行分析总结。结果98例经充分术前准备和精确的心功能评估达手术要求,再配合术中恰当的麻醉、轻柔快捷的手术、合理的术后处理,本组除1例中止手术外,其余均顺利完成手术,围术期无心血管并发症出现。结论甲亢性心脏病并非甲亢手术的禁忌证,A-B级心功能下进行手术是安全的。     

甲状腺次全切除术的治疗分析及并发症的预防

目的:探讨甲状腺功能亢进次全切除术的治疗方法及并发症的预防。方法:回顾性分析120例因甲状腺功能亢进行甲状腺次全切除术的临床资料,探讨术后并发症的发生原因和预防措施。结果:患者全部治愈出院,无甲状腺危象、声音嘶哑等严重并发症发生。结论:严格做好术前准备,术中操作轻柔,彻底止血,囊内结扎甲状腺上、下极血管,并根据中毒症状、病程长短、年龄、腺体的大小决定保留腺体数量,有助于进一步减少并发症,提高治愈率。     

甲状腺机能亢进症围手术期的处理

为探讨甲状腺机能亢进症的手术治疗效果，对１０３８例甲状腺机能亢进症病人的围手术期处理情况进行了分析。结果：术后无１例发生甲状腺危象。术后２年以上者９８０例，均获随访（１００％），随访时间为２～１５年，治愈率为９９．１％；复发９例，占０．９％。